ProMIS Neurosciences (PMN) Operating Expenses (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Operating Expenses came in at $8.6 million in Q1 2026, up 15.88% YoY from $7.5 million in Q1 2025, and down 19.75% on a QoQ basis from $10.8 million in Q4 2025.
ProMIS Neurosciences (PMN) Operating Expenses (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Operating Expenses data on file, last reported at $8.6 million in Q1 2026.
- Quarterly Operating Expenses rose 15.88% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.4 million (up 100.63% YoY) and the FY2025 annual result came in at $40.2 million, up 138.7% from the prior year.
- Operating Expenses eased to $8.6 million in Q1 2026, from $10.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $11.8 million in Q3 2025 to a low of $2.5 million in Q3 2023.
- A 5-year average of $6.1 million and a median of $5.0 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 340.07% — and 2023, when it plunged 58.42%.
- Tracing PMN's Operating Expenses over 5 years: stood at $8.5 million in 2022, then slumped by 54.54% to $3.9 million in 2023, then surged by 54.92% to $6.0 million in 2024, then surged by 79.46% to $10.8 million in 2025, then fell by 19.75% to $8.6 million in 2026.
- The last three Operating Expenses figures came in at $8.6 million (Q1 2026), $10.8 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 541.02 Mn |
| 10 | ProMIS Neurosciences | 135.63 Mn | 82.16 Mn | - | 12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.27 Mn |
| Mar 31, 2026 | 8.64 Mn |
| Dec 31, 2025 | 10.77 Mn |
| Sep 30, 2025 | 11.75 Mn |
| Jun 30, 2025 | 10.18 Mn |
| Mar 31, 2025 | 7.46 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Sep 30, 2024 | 4.43 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Dec 31, 2023 | 3.87 Mn |
| Sep 30, 2023 | 2.52 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 4.97 Mn |
| Dec 31, 2022 | 8.52 Mn |
| Sep 30, 2022 | 6.05 Mn |
| Jun 30, 2022 | 4.86 Mn |
| Mar 31, 2022 | 3.94 Mn |
| Dec 31, 2021 | 4.55 Mn |
| Sep 30, 2021 | 2.07 Mn |